fluorouracil has been researched along with Hypopharyngeal Cancer in 111 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin." | 7.70 | Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. ( Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB, 1999) |
| "Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included." | 6.71 | Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003) |
| " We conducted a retrospective study to evaluate the efficacy of this protocol with taxene, cisplatin and 5-fluorouracil in Chinese patients with hypopharyngeal cancer that chose preservation strategy." | 3.88 | Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer. ( Bai, Y; Fang, J; Feng, L; Hou, L; Li, P; Lian, M; Liu, S; Ma, H; Meng, L; Zhong, Q, 2018) |
| "In order to make possible organ preservation, since 2007 our hospital has performed induction chemotherapy (ICT) with cisplatin and 5-fluorouracil (PF) for hypopharyngeal cancer as chemoselection, followed by alternating chemoradiotherapy (ACRT) with docetaxel, cisplatin, and 5-fluorouracil in (TPF) good responders and curative surgery was used in poor responders." | 3.83 | Chemoselection combined with alternating chemoradiotherapy or surgery for hypopharyngeal cancer. ( Ikeda, M; Imaizumi, M; Matsui, T; Matsuzuka, T; Nakaegawa, Y; Nomoto, M; Nomoto, Y; Omori, K; Saijoh, S; Sato, H; Suzuki, M; Suzuki, R; Suzuki, Y; Tada, Y; Tani, A, 2016) |
| "In head and neck cancer including hypopharyngeal cancer, cisplatin and 5-fluorouracil (5-FU) usually have been used as neoadjuvant chemotherapeutic agents." | 3.73 | Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line. ( An, WG; Chon, KM; Goh, EK; Kim, YS; Lee, BJ; Roh, HJ; Wang, SG, 2005) |
| "A 58-year-old man with hypopharyngeal cancer who developed 5-fluorouracil-induced leukoencephalopathy." | 3.73 | Reversible impairment of auditory callosal pathway in 5-fluorouracil-induced leukoencephalopathy: parallel changes in function and imaging. ( Fujimoto, C; Ito, K; Iwasaki, S; Nakao, K; Sugasawa, M, 2006) |
| "We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin." | 3.70 | Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. ( Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB, 1999) |
| "Acute Grade 3 (G3) dysphagia was higher in DL2 (87% DL2 vs." | 2.77 | Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. ( A'hern, R; Barbachano, Y; Bhide, SA; Bidmead, AM; Clark, C; Guerrero-Urbano, MT; Harrington, KJ; Hickey, J; Miah, AB; Newbold, KL; Nicol, R; Nutting, CM; St Rose, S; Tanay, M, 2012) |
| "Objectives were to assess maximum tolerated dose, dose-limiting toxicity (DLT) and to recommend a safe dose of LAP when administered with 4 cycles of TPF followed by CRT." | 2.77 | EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. ( Andry, G; Awada, A; Bogaerts, J; El-Hariry, I; Fortpied, C; Lacombe, D; Lalami, Y; Langendijk, JA; Liberatoscioli, C; Specenier, PM; Vermorken, JB, 2012) |
| "0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy." | 2.76 | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. ( Debus, J; Desta, A; Habl, G; Jensen, AD; Krauss, J; Mavtratzas, A; Münter, MW; Potthoff, K; Windemuth-Kiesselbach, C, 2011) |
| "For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy." | 2.75 | Chemotherapy alone for organ preservation in advanced laryngeal cancer. ( Bradford, CR; Chepeha, DB; Divi, V; Eisbruch, A; Hogikyan, ND; Lee, JS; Moyer, JS; Prince, ME; Teknos, TN; Tsien, CI; Urba, SG; Wolf, GT; Worden, FP, 2010) |
| "Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included." | 2.71 | Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003) |
| "Treatment with sodium selenite is well tolerated and easy to deliver." | 2.71 | Selenium in the treatment of radiation-associated secondary lymphedema. ( Bruns, F; Büntzel, J; DeVries, AF; Glatzel, M; Kisters, K; Micke, O; Mücke, R; Schäfer, U; Schönekaes, K, 2003) |
| "The histology was squamous cell carcinoma in 44 patients and adenocarcinoma in 3 patients with esophagus cancer." | 2.68 | Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. ( Beattie, E; Malamud, S; Nussbaum, M; Vikram, B; Yu, L; Yudelman, I, 1995) |
| "To analyze clinical and pharmacokinetic data of cisplatin (CP)/fluorouracil (FU)/l folinic acid (l FA) chemotherapy administered as first-line treatment to locally advanced head and neck cancer patients." | 2.68 | Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ( Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995) |
| "Hypopharyngeal cancer is a relatively rare malignancy with poor prognosis." | 1.72 | Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents. ( Eguchi, H; Grénman, R; Kawabata-Iwakawa, R; Kawata-Shimamura, Y; Nakahira, M; Nishiyama, M; Okazaki, Y; Sugasawa, M; Yoda, T, 2022) |
| "Head and neck squamous cell carcinomas (HNSCCs) are characterized by marked heterogeneity in their biological behavior and response to treatment." | 1.40 | p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. ( Fresno, MF; García-Pedrero, JM; Hermsen, M; Moreno-Galindo, C; Rodrigo, JP; Suárez, C, 2014) |
| "Mucositis was the major acute toxicity, but this was well tolerated in most subjects." | 1.36 | Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study. ( Fujii, M; Fukada, J; Kawaguchi, O; Kubo, A; Kunieda, E; Ohashi, T; Shigematsu, N; Shiotani, A; Takeda, A; Tomita, T, 2010) |
| "Patients receiving C-IMRT for head-and-neck cancer had repeat CT scans at weeks 2, 3, 4, and 5 during radiotherapy." | 1.36 | Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. ( Barbachano, Y; Bhide, SA; Burke, K; Davies, M; El-Hariry, IA; Hansen, V; Harrington, KJ; McNair, HA; Newbold, K; Nutting, CM, 2010) |
| "Patients presenting with squamous cell carcinoma of the pyriform sinus, epilarynx or postcricoid area with indication of pharyngolaryngectomy, without previous treatment, distant metastasis, multiple primaries or general contraindications for surgery and chemotherapy were included in the study." | 1.29 | [Perioperative chemotherapy of squamous cell carcinoma of the hypopharynx]. ( Domenge, C; Eschwège, F; Leridant, AM; Luboinski, B; Mamelle, G; Wibault, P, 1996) |
| "Average survival for advanced head and neck cancer (AHNC) is 18 months." | 1.27 | Pretreatment with chemotherapy in patients with advanced head and neck cancer. ( Barron, P; Cripps, C; Danjoux, C; de la Bastide, Y; Hardie, J; Nichol, J; Odell, P, 1985) |
| "Fifty-seven patients with advanced squamous carcinoma of the larynx and hypopharynx were entered on a pilot study of initial therapy using split course radiation therapy combined with simultaneous chemotherapy using mitomycin-C and 5-fluorouracil." | 1.27 | A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx. ( Beale, FA; Cummings, BJ; Elhakim, T; Harwood, AR; Keane, TJ; Payne, DG; Rawlinson, E, 1986) |
| "One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract (UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of chemotherapy before any local treatment." | 1.27 | Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. ( Caldani, C; Chauvel, P; Demard, F; Santini, J; Schneider, M; Thyss, A; Vallicioni, J, 1986) |
| "The treatment of 192 patients with cancer of the larynx, 60 patients with hypopharyngeal and cervical esophageal cancer, and 23 patients with epipharyngeal cancer with FAR therapy during 6 years from 1972 to 1977 resulted in highly effective synergism, and the improved points of this therapy were considered." | 1.27 | Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A. ( Komiyama, S; Kudoh, S; Kuwano, M; Yanagita, T, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (4.50) | 18.7374 |
| 1990's | 23 (20.72) | 18.2507 |
| 2000's | 42 (37.84) | 29.6817 |
| 2010's | 37 (33.33) | 24.3611 |
| 2020's | 4 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| Kawata-Shimamura, Y | 1 |
| Eguchi, H | 1 |
| Kawabata-Iwakawa, R | 1 |
| Nakahira, M | 1 |
| Okazaki, Y | 1 |
| Yoda, T | 1 |
| Grénman, R | 1 |
| Sugasawa, M | 2 |
| Nishiyama, M | 1 |
| Hitt, R | 1 |
| Iglesias, L | 1 |
| López-Pousa, A | 1 |
| Berrocal-Jaime, A | 1 |
| Grau, JJ | 1 |
| García-Girón, C | 1 |
| Martínez-Trufero, J | 1 |
| Guix, M | 1 |
| Lambea-Sorrosal, J | 1 |
| Del Barco-Morillo, E | 1 |
| León-Vintró, X | 1 |
| Cunquero-Tomas, AJ | 1 |
| Baste, N | 1 |
| Ocaña, A | 1 |
| Cruz-Hernández, JJ | 1 |
| Sahashi, Y | 1 |
| Nawa, T | 1 |
| Echanique, KA | 1 |
| Evans, LK | 1 |
| Han, AY | 1 |
| Chhetri, DK | 1 |
| St John, MA | 1 |
| Hess, AK | 1 |
| Müer, A | 1 |
| Mairinger, FD | 1 |
| Weichert, W | 1 |
| Stenzinger, A | 1 |
| Hummel, M | 1 |
| Budach, V | 4 |
| Tinhofer, I | 1 |
| Zhong, Q | 2 |
| Fang, J | 2 |
| Huang, Z | 1 |
| Yang, Y | 1 |
| Lian, M | 2 |
| Liu, H | 1 |
| Zhang, Y | 1 |
| Ye, J | 1 |
| Hui, X | 1 |
| Wang, Y | 1 |
| Ying, Y | 1 |
| Zhang, Q | 2 |
| Cheng, Y | 1 |
| Dietz, A | 5 |
| Wichmann, G | 1 |
| Kuhnt, T | 1 |
| Pfreundner, L | 2 |
| Hagen, R | 2 |
| Scheich, M | 1 |
| Kölbl, O | 1 |
| Hautmann, MG | 1 |
| Strutz, J | 1 |
| Schreiber, F | 1 |
| Bockmühl, U | 1 |
| Schilling, V | 1 |
| Feyer, P | 1 |
| de Wit, M | 1 |
| Maschmeyer, G | 1 |
| Jungehülsing, M | 1 |
| Schroeder, U | 2 |
| Wollenberg, B | 1 |
| Sittel, C | 1 |
| Münter, M | 1 |
| Lenarz, T | 1 |
| Klussmann, JP | 1 |
| Guntinas-Lichius, O | 2 |
| Rudack, C | 1 |
| Eich, HT | 2 |
| Foerg, T | 1 |
| Preyer, S | 1 |
| Westhofen, M | 2 |
| Welkoborsky, HJ | 2 |
| Esser, D | 1 |
| Thurnher, D | 1 |
| Remmert, S | 1 |
| Sudhoff, H | 1 |
| Görner, M | 1 |
| Bünzel, J | 1 |
| Held, S | 1 |
| Knödler, M | 1 |
| Lordick, F | 1 |
| Wiegand, S | 1 |
| Vogel, K | 1 |
| Boehm, A | 1 |
| Flentje, M | 4 |
| Keilholz, U | 2 |
| Liu, S | 1 |
| Ma, H | 1 |
| Meng, L | 1 |
| Bai, Y | 1 |
| Feng, L | 1 |
| Li, P | 1 |
| Hou, L | 1 |
| Sun, W | 1 |
| Chen, L | 1 |
| Huang, JQ | 1 |
| Li, J | 1 |
| Zhu, XL | 1 |
| Wen, YH | 1 |
| Wen, WP | 1 |
| Suzuki, K | 1 |
| Hayashi, R | 3 |
| Ebihara, M | 1 |
| Miyazaki, M | 2 |
| Shinozaki, T | 1 |
| Daiko, H | 1 |
| Sakuraba, M | 2 |
| Zenda, S | 2 |
| Tahara, M | 3 |
| Fujii, S | 1 |
| Moreno-Galindo, C | 1 |
| Hermsen, M | 1 |
| García-Pedrero, JM | 1 |
| Fresno, MF | 1 |
| Suárez, C | 1 |
| Rodrigo, JP | 1 |
| Maggiore, RJ | 1 |
| Curran, EK | 1 |
| Witt, ME | 1 |
| Haraf, DJ | 1 |
| Vokes, EE | 1 |
| Cohen, EE | 1 |
| Sato, K | 2 |
| Kubota, A | 1 |
| Furukawa, M | 1 |
| Kitani, Y | 1 |
| Nakayama, Y | 1 |
| Nonaka, T | 1 |
| Mizoguchi, N | 1 |
| Shiomi, M | 1 |
| Zhang, X | 1 |
| Wang, J | 1 |
| Wu, W | 1 |
| Ma, L | 1 |
| Liu, M | 1 |
| Zhao, F | 1 |
| Huang, D | 1 |
| Stromberger, C | 1 |
| Poettgen, C | 1 |
| Baumann, M | 1 |
| Budach, W | 1 |
| Grabenbauer, G | 1 |
| Marnitz, S | 1 |
| Olze, H | 1 |
| Wernecke, KD | 1 |
| Ghadjar, P | 1 |
| Yoon, TM | 1 |
| Kim, SA | 1 |
| Lee, DH | 1 |
| Lee, JK | 3 |
| Park, YL | 1 |
| Lee, KH | 1 |
| Chung, IJ | 1 |
| Joo, YE | 1 |
| Lim, SC | 2 |
| Bozec, A | 1 |
| Benezery, K | 2 |
| Chamorey, E | 3 |
| Ettaiche, M | 1 |
| Vandersteen, C | 1 |
| Dassonville, O | 4 |
| Poissonnet, G | 3 |
| Riss, JC | 1 |
| Hannoun-Lévi, JM | 1 |
| Chand, ME | 1 |
| Leysalle, A | 1 |
| Saada, E | 1 |
| Sudaka, A | 1 |
| Haudebourg, J | 1 |
| Hebert, C | 1 |
| Falewee, MN | 1 |
| Demard, F | 7 |
| Santini, J | 4 |
| Peyrade, F | 2 |
| Matsuzuka, T | 1 |
| Sato, H | 1 |
| Suzuki, R | 1 |
| Suzuki, M | 1 |
| Saijoh, S | 1 |
| Ikeda, M | 2 |
| Nakaegawa, Y | 1 |
| Tani, A | 1 |
| Imaizumi, M | 1 |
| Matsui, T | 1 |
| Nomoto, Y | 1 |
| Nomoto, M | 1 |
| Tada, Y | 1 |
| Suzuki, Y | 1 |
| Omori, K | 1 |
| Janoray, G | 1 |
| Pointreau, Y | 2 |
| Garaud, P | 2 |
| Chapet, S | 2 |
| Alfonsi, M | 2 |
| Sire, C | 2 |
| Jadaud, E | 1 |
| Calais, G | 3 |
| Yanagi, T | 1 |
| Shibamoto, Y | 1 |
| Ogino, H | 1 |
| Baba, F | 1 |
| Murai, T | 1 |
| Nagai, A | 1 |
| Miyakawa, A | 1 |
| Sugie, C | 1 |
| Li, L | 1 |
| Tan, F | 1 |
| Yue, W | 1 |
| Wang, H | 2 |
| Xue, H | 1 |
| Wen, Z | 1 |
| Henriques De Figueiredo, B | 1 |
| Fortpied, C | 2 |
| Menis, J | 1 |
| Lefebvre, JL | 3 |
| Barzan, L | 1 |
| de Raucourt, D | 1 |
| Geoffrois, L | 1 |
| Giurgea, L | 1 |
| Hupperets, P | 1 |
| Leemans, CR | 1 |
| Licitra, L | 2 |
| Rolland, F | 1 |
| Tesselaar, M | 1 |
| Vermorken, JB | 3 |
| Grégoire, V | 1 |
| Bossi, P | 1 |
| Bergamini, C | 1 |
| Miceli, R | 1 |
| Cova, A | 1 |
| Orlandi, E | 1 |
| Resteghini, C | 1 |
| Locati, L | 1 |
| Alfieri, S | 1 |
| Imbimbo, M | 1 |
| Granata, R | 1 |
| Mariani, L | 1 |
| Iacovelli, NA | 1 |
| Huber, V | 1 |
| Cavallo, A | 1 |
| Rivoltini, L | 1 |
| Nakashima, T | 3 |
| Yasumatsu, R | 2 |
| Asai, K | 1 |
| Uryu, H | 1 |
| Kogo, R | 1 |
| Nakagawa, T | 2 |
| Sakaguchi, M | 1 |
| Maebayashi, T | 1 |
| Aizawa, T | 1 |
| Ishibashi, N | 1 |
| Saito, T | 2 |
| Otsuki, N | 1 |
| Masai, Y | 1 |
| Sasaki, R | 1 |
| Tsukuda, M | 3 |
| Nibu, K | 1 |
| Tai, SK | 1 |
| Yang, MH | 1 |
| Wang, LW | 1 |
| Tsai, TL | 1 |
| Chu, PY | 1 |
| Wang, YF | 1 |
| Huang, JL | 1 |
| Chang, SY | 1 |
| Rodriguez, CP | 1 |
| Adelstein, DJ | 2 |
| Rybicki, LA | 1 |
| Saxton, JP | 1 |
| Lorenz, RR | 1 |
| Wood, BG | 1 |
| Strome, M | 1 |
| Esclamado, RM | 1 |
| Lavertu, P | 1 |
| Carroll, MA | 1 |
| Forastiere, AA | 1 |
| Trotti, AM | 1 |
| Posner, MR | 1 |
| Norris, CM | 1 |
| Wirth, LJ | 1 |
| Shin, DM | 1 |
| Cullen, KJ | 1 |
| Winquist, EW | 1 |
| Blajman, CR | 1 |
| Mickiewicz, EA | 1 |
| Frenette, GP | 1 |
| Plinar, LF | 1 |
| Cohen, RB | 1 |
| Steinbrenner, LM | 1 |
| Freue, JM | 1 |
| Gorbunova, VA | 1 |
| Tjulandin, SA | 1 |
| Raez, LE | 1 |
| Adkins, DR | 1 |
| Tishler, RB | 1 |
| Roessner, MR | 1 |
| Haddad, RI | 1 |
| Tuchais, C | 1 |
| Tortochaux, J | 2 |
| Faivre, S | 1 |
| Guerrif, S | 1 |
| Fukada, J | 1 |
| Shigematsu, N | 1 |
| Takeda, A | 1 |
| Ohashi, T | 1 |
| Tomita, T | 1 |
| Shiotani, A | 1 |
| Kunieda, E | 1 |
| Kawaguchi, O | 1 |
| Fujii, M | 1 |
| Kubo, A | 1 |
| Prades, JM | 2 |
| Lallemant, B | 1 |
| Garrel, R | 1 |
| Reyt, E | 1 |
| Righini, C | 1 |
| Schmitt, T | 1 |
| Remini, N | 1 |
| Saban-Roche, L | 1 |
| Timoshenko, AP | 2 |
| Trombert, B | 1 |
| Guerrier, B | 1 |
| Matsutani, T | 1 |
| Sasajima, K | 1 |
| Kobayashi, Y | 1 |
| Suzuki, S | 2 |
| Maruyama, H | 1 |
| Miyamoto, M | 1 |
| Yokoyama, T | 1 |
| Sugiura, A | 1 |
| Matsushita, A | 1 |
| Yanagi, K | 1 |
| Matsuda, A | 2 |
| Arai, H | 1 |
| Nishi, Y | 1 |
| Wakabayashi, H | 1 |
| Tajiri, T | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 1 |
| Tsubosaka, T | 1 |
| Tsutsumi, T | 1 |
| Karaho, T | 1 |
| Kohno, N | 1 |
| Divi, V | 1 |
| Worden, FP | 1 |
| Prince, ME | 1 |
| Eisbruch, A | 2 |
| Lee, JS | 1 |
| Bradford, CR | 2 |
| Chepeha, DB | 1 |
| Teknos, TN | 1 |
| Hogikyan, ND | 1 |
| Moyer, JS | 1 |
| Tsien, CI | 1 |
| Urba, SG | 3 |
| Wolf, GT | 2 |
| Liu, WS | 1 |
| Hsin, CH | 1 |
| Chou, YH | 1 |
| Liu, JT | 1 |
| Wu, MF | 1 |
| Tseng, SW | 1 |
| Tseng, HC | 1 |
| Wang, TH | 1 |
| Su, MC | 1 |
| Lee, H | 1 |
| Bhide, SA | 2 |
| Davies, M | 1 |
| Burke, K | 1 |
| McNair, HA | 1 |
| Hansen, V | 1 |
| Barbachano, Y | 2 |
| El-Hariry, IA | 1 |
| Newbold, K | 1 |
| Harrington, KJ | 2 |
| Nutting, CM | 2 |
| Huang, WY | 1 |
| Jen, YM | 1 |
| Chen, CM | 1 |
| Su, YF | 1 |
| Lin, CS | 1 |
| Lin, YS | 1 |
| Chang, YN | 1 |
| Chao, HL | 1 |
| Lin, KT | 1 |
| Chang, LP | 1 |
| Yang, L | 1 |
| Chen, WK | 1 |
| Guo, ZM | 1 |
| Gu, MF | 1 |
| Huang, HQ | 1 |
| Yang, AK | 1 |
| Habl, G | 2 |
| Jensen, AD | 2 |
| Potthoff, K | 2 |
| Uhl, M | 1 |
| Hof, H | 1 |
| Hajda, J | 1 |
| Simon, C | 1 |
| Debus, J | 2 |
| Krempien, R | 1 |
| Münter, MW | 2 |
| Okumura, Y | 1 |
| Ryotokuji, T | 1 |
| Miura, A | 1 |
| Kato, T | 1 |
| Tomemori, T | 1 |
| Mitsuhashi, T | 1 |
| Monma, K | 1 |
| Izumi, Y | 1 |
| Miah, AB | 1 |
| Guerrero-Urbano, MT | 1 |
| Clark, C | 1 |
| Bidmead, AM | 1 |
| St Rose, S | 1 |
| A'hern, R | 1 |
| Tanay, M | 1 |
| Hickey, J | 1 |
| Nicol, R | 1 |
| Newbold, KL | 1 |
| Krauss, J | 1 |
| Desta, A | 1 |
| Mavtratzas, A | 1 |
| Windemuth-Kiesselbach, C | 1 |
| Kawashima, M | 2 |
| Arahira, S | 2 |
| Ogino, T | 2 |
| Chitose, S | 1 |
| Chijiwa, H | 1 |
| Maeda, A | 1 |
| Umeno, H | 1 |
| Kiyokawa, K | 1 |
| Hayabuchi, N | 1 |
| Fujita, H | 1 |
| Tomita, M | 1 |
| Matsuyama, H | 1 |
| Yamazaki, K | 1 |
| Takahashi, S | 1 |
| Lalami, Y | 1 |
| Specenier, PM | 1 |
| Awada, A | 1 |
| Lacombe, D | 1 |
| Liberatoscioli, C | 1 |
| El-Hariry, I | 1 |
| Bogaerts, J | 1 |
| Andry, G | 1 |
| Langendijk, JA | 1 |
| Furusaka, T | 1 |
| Tanaka, A | 1 |
| Matsuda, H | 2 |
| Watanabe, A | 1 |
| Taniguchi, M | 1 |
| Kawabori, S | 1 |
| Chesnay, E | 1 |
| Babin, E | 1 |
| Constans, JM | 1 |
| Agostini, D | 1 |
| Bequignon, A | 1 |
| Regeasse, A | 1 |
| Sobrio, F | 1 |
| Moreau, S | 1 |
| Micke, O | 1 |
| Bruns, F | 1 |
| Mücke, R | 1 |
| Schäfer, U | 1 |
| Glatzel, M | 1 |
| DeVries, AF | 1 |
| Schönekaes, K | 1 |
| Kisters, K | 1 |
| Büntzel, J | 1 |
| Schmidberger, H | 1 |
| Rave-Fränk, M | 1 |
| Kim, S | 1 |
| Hille, A | 1 |
| Pradier, O | 1 |
| Hess, CF | 1 |
| Miyahara, H | 1 |
| Nario, K | 1 |
| Matsushiro, N | 1 |
| Sasai, H | 1 |
| Kajikawa, H | 1 |
| Rudat, V | 3 |
| Hoppe, F | 1 |
| Kuratomi, Y | 2 |
| Yamamoto, T | 1 |
| Kumamoto, Y | 1 |
| Masuda, M | 1 |
| Koike, K | 1 |
| Komiyama, S | 3 |
| Altundag, O | 1 |
| Gullu, I | 1 |
| Altundag, K | 1 |
| Yalcin, S | 1 |
| Ozyar, E | 1 |
| Cengiz, M | 1 |
| Akyol, F | 1 |
| Yucel, T | 1 |
| Hosal, S | 1 |
| Sozeri, B | 1 |
| Moon, J | 1 |
| Giri, PG | 1 |
| Hanna, E | 1 |
| Yoo, GH | 1 |
| Leblanc, M | 1 |
| Ensley, JF | 1 |
| Schuller, DE | 1 |
| Bourhis, J | 1 |
| Temam, S | 1 |
| Lusinchi, A | 1 |
| Janot, F | 1 |
| Wibault, P | 3 |
| Pignon, JP | 1 |
| Chan, L | 1 |
| Yeo, W | 1 |
| Leung, SF | 1 |
| Griffith, J | 1 |
| Ng, EK | 1 |
| Chan, AT | 1 |
| Lee, BJ | 1 |
| Chon, KM | 1 |
| Kim, YS | 1 |
| An, WG | 1 |
| Roh, HJ | 1 |
| Goh, EK | 1 |
| Wang, SG | 1 |
| Yom, SS | 1 |
| Machtay, M | 1 |
| Biel, MA | 1 |
| Sinard, RJ | 1 |
| El-Naggar, AK | 1 |
| Weber, RS | 1 |
| Rosenthal, DI | 1 |
| Puri, DR | 1 |
| Chou, W | 1 |
| Lee, N | 1 |
| Endo, S | 1 |
| Tsuji, K | 1 |
| Nomura, Y | 1 |
| Noguchi, Y | 1 |
| Kida, A | 1 |
| Tanaka, Y | 1 |
| Bensadoun, RJ | 3 |
| Magné, N | 2 |
| Ramaïoli, A | 1 |
| Lemanski, C | 1 |
| Bourdin, S | 3 |
| Marcy, PY | 3 |
| Vallicioni, J | 3 |
| Seng, H | 1 |
| Alzieu, C | 1 |
| Géry, B | 1 |
| Chauvel, P | 3 |
| Schneider, M | 5 |
| Semrau, R | 1 |
| Mueller, RP | 2 |
| Stuetzer, H | 2 |
| Staar, S | 2 |
| Kocher, M | 1 |
| Volling, P | 2 |
| Schroeder, M | 2 |
| Eckel, HE | 2 |
| Fujimoto, C | 1 |
| Ito, K | 2 |
| Iwasaki, S | 1 |
| Nakao, K | 1 |
| Yip, KW | 1 |
| Ito, E | 1 |
| Mao, X | 1 |
| Au, PY | 1 |
| Hedley, DW | 1 |
| Mocanu, JD | 1 |
| Bastianutto, C | 1 |
| Schimmer, A | 1 |
| Liu, FF | 1 |
| Lee, NY | 1 |
| O'Meara, W | 1 |
| Chan, K | 1 |
| Della-Bianca, C | 1 |
| Mechalakos, JG | 1 |
| Zhung, J | 1 |
| Wolden, SL | 1 |
| Narayana, A | 1 |
| Kraus, D | 1 |
| Shah, JP | 1 |
| Pfister, DG | 1 |
| Nishimura, G | 2 |
| Horiuchi, C | 1 |
| Satake, K | 1 |
| Yoshida, T | 1 |
| Nagao, J | 1 |
| Kawakami, M | 1 |
| Kondo, N | 1 |
| Arai, Y | 1 |
| Taguchi, T | 1 |
| Mikami, Y | 1 |
| Fujii, H | 1 |
| Nasu, K | 1 |
| Lee, MS | 1 |
| Ho, HC | 1 |
| Hsiao, SH | 1 |
| Hwang, JH | 1 |
| Lee, CC | 1 |
| Hung, SK | 1 |
| Wadasaki, K | 1 |
| Matsuura, K | 1 |
| Murakami, Y | 1 |
| Kenjo, M | 1 |
| Kaneyasu, Y | 1 |
| Fujita, M | 1 |
| Tatsukawa, R | 1 |
| Takeno, Y | 1 |
| Hirakawa, K | 1 |
| Werner, J | 1 |
| Iro, H | 2 |
| Yoon, MS | 1 |
| Chung, WK | 1 |
| Ahn, SJ | 1 |
| Nam, TK | 1 |
| Nah, BS | 1 |
| Song, JY | 1 |
| Yu, L | 1 |
| Vikram, B | 2 |
| Malamud, S | 1 |
| Yudelman, I | 1 |
| Nussbaum, M | 1 |
| Beattie, E | 1 |
| Etienne, MC | 2 |
| Milano, G | 2 |
| Thyss, A | 3 |
| Otto, J | 1 |
| Mobayen, H | 1 |
| Saudes, L | 1 |
| Guillot, T | 1 |
| Reisser, C | 1 |
| Haberkorn, U | 2 |
| Dimitrakopoulou-Strauss, A | 1 |
| Seifert, E | 2 |
| Strauss, LG | 2 |
| Thomas, C | 1 |
| Koh, WJ | 1 |
| Keane, TJ | 2 |
| Cummings, BJ | 2 |
| O'Sullivan, B | 1 |
| Payne, D | 1 |
| Rawlinson, E | 2 |
| MacKenzie, R | 1 |
| Danjoux, C | 2 |
| Hodson, I | 1 |
| Gedouin, D | 1 |
| Desprez, P | 1 |
| Perron, JJ | 1 |
| Fleury, F | 1 |
| Leclech, G | 1 |
| Miglianico, L | 1 |
| Belpomme, D | 1 |
| Chenal, C | 1 |
| Mamelle, G | 1 |
| Domenge, C | 1 |
| Eschwège, F | 1 |
| Leridant, AM | 1 |
| Luboinski, B | 2 |
| de Crevoisier, R | 1 |
| Mazeron, JJ | 1 |
| Kievit, E | 1 |
| Pinedo, HM | 1 |
| Schlüper, HM | 1 |
| Haisma, HJ | 1 |
| Boven, E | 1 |
| Beauvillain, C | 1 |
| Mahé, M | 1 |
| Peuvrel, P | 1 |
| Bergerot, P | 1 |
| Rivière, A | 1 |
| Vignoud, J | 1 |
| Deraucourt, D | 1 |
| Wesoluch, M | 1 |
| Schrader, M | 1 |
| Schipper, J | 1 |
| Jahnke, K | 1 |
| Stuschke, M | 1 |
| Sack, H | 1 |
| Yamaoka, H | 1 |
| Mochimatsu, I | 1 |
| Nagahara, T | 1 |
| Enomoto, H | 1 |
| Kagata, H | 1 |
| Kagesato, Y | 1 |
| Daicho, S | 1 |
| Mizuno, H | 1 |
| Baba, Y | 1 |
| Kawakami, K | 1 |
| Julieron, M | 1 |
| Germain, MA | 1 |
| Schwaab, G | 1 |
| Marandas, P | 1 |
| Bourgain, JL | 1 |
| Pivot, X | 2 |
| Prevost, B | 1 |
| Coche-Dequeant, B | 1 |
| Courdi, A | 1 |
| Teissier, E | 1 |
| Lagrange, JL | 1 |
| Van den Brande, J | 1 |
| Schrijvers, D | 1 |
| Colpaert, C | 1 |
| Thornton, AF | 1 |
| Terrell, JE | 1 |
| Carpenter, V | 1 |
| Miller, T | 1 |
| Tang, G | 1 |
| Strawderman, M | 1 |
| Lorenz, M | 1 |
| Regele, H | 1 |
| Kovarik, J | 1 |
| Hörl, WH | 1 |
| Klauser, R | 1 |
| Guardiola, E | 1 |
| Amin, R | 1 |
| Akisada, T | 1 |
| Harada, T | 1 |
| Takemoto, T | 1 |
| Fukuda, K | 1 |
| Morita, N | 1 |
| Aihara, T | 1 |
| Kajihara, Y | 1 |
| Imai, S | 1 |
| Gyoten, M | 1 |
| Imajo, Y | 1 |
| Hiratsuka, J | 1 |
| Schmitt, TM | 1 |
| Simon, PG | 1 |
| de Cornulier, J | 1 |
| Durand, M | 1 |
| Guillot, A | 1 |
| Martin, C | 1 |
| Sarini, J | 1 |
| Bocciolini, C | 1 |
| Fournier, C | 1 |
| Penel, N | 1 |
| Kara, A | 1 |
| Van, JT | 1 |
| Bauer, FP | 1 |
| Schadel, A | 1 |
| Bleier, R | 1 |
| Wissen-Siegert, I | 1 |
| Karp, DD | 1 |
| Vaughan, CW | 1 |
| Carter, R | 1 |
| Willett, B | 1 |
| Heeren, T | 1 |
| Calarese, P | 1 |
| Zeitels, S | 1 |
| Strong, MS | 1 |
| Hong, WK | 1 |
| Masuda, A | 1 |
| Tomita, K | 1 |
| Zingu, K | 1 |
| Fietkau, R | 1 |
| Grabenbauer, GG | 1 |
| Altendorf-Hofmann, A | 1 |
| Sauer, R | 1 |
| Laccourreye, H | 1 |
| Bassot, V | 1 |
| Lacau St Guily, J | 1 |
| Brasnu, D | 1 |
| Menard, M | 1 |
| Donnadieu, S | 1 |
| Jacquillat, C | 1 |
| Cripps, C | 1 |
| Odell, P | 1 |
| Nichol, J | 1 |
| de la Bastide, Y | 1 |
| Barron, P | 1 |
| Hardie, J | 1 |
| Harwood, AR | 1 |
| Beale, FA | 1 |
| Payne, DG | 1 |
| Elhakim, T | 1 |
| Caldani, C | 1 |
| Kudoh, S | 1 |
| Yanagita, T | 1 |
| Kuwano, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck[NCT00261703] | Phase 2/Phase 3 | 439 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx[NCT00508664] | Phase 2 | 180 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation[NCT06137378] | Phase 2 | 140 participants (Anticipated) | Interventional | 2024-11-30 | Not yet recruiting | ||
| Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma[NCT04995120] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122] | 400 participants (Anticipated) | Observational | 2017-02-02 | Recruiting | |||
| New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma[NCT03558035] | Phase 2 | 96 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma[NCT00498953] | Phase 1/Phase 2 | 7 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| The Role of Sodium Selenite Supplementation in Patients With Locally Advanced Head and Neck Cancer Undergoing Concurrent Chemoradiotherapy[NCT05451576] | 60 participants (Anticipated) | Interventional | 2020-08-12 | Recruiting | |||
| Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II[NCT00002735] | Phase 2 | 68 participants (Actual) | Interventional | 1996-04-30 | Terminated (stopped due to Terminated due to poor accrual.) | ||
| Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx[NCT00003627] | Phase 3 | 160 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
6 reviews available for fluorouracil and Hypopharyngeal Cancer
| Article | Year |
|---|---|
Cancer of the Larynx and Hypopharynx.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 2021 |
Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Hyp | 2004 |
[Larynx preservation: nonsurgical approaches].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2004 |
[Current role for induction chemotherapy in head and neck tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
[Update on cancerology of the upper aerodigestive tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Transplantation; Clinical Tr | 1998 |
Sustained complete remission of stage IV carcinoma of the pyriform fossa following chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2002 |
33 trials available for fluorouracil and Hypopharyngeal Cancer
| Article | Year |
|---|---|
MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; C | 2017 |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Cisplatin; Female; Fluorouracil; Head an | 2018 |
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin | 2018 |
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin | 2018 |
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin | 2018 |
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin | 2018 |
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Long-term update of the 24954 EORTC phase III trial on larynx preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Femal | 2017 |
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2009 |
Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; | 2010 |
Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2009 |
Chemotherapy alone for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modal | 2010 |
Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2012 |
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem | 2012 |
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2012 |
Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2003 |
Selenium in the treatment of radiation-associated secondary lymphedema.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 2003 |
Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2005 |
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 2006 |
Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1995 |
Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1993 |
[Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Fluoro | 1996 |
[Apropos of two recently published randomized trials of induction chemotherapy in nasopharyngeal and piriform sinus carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Comb | 1996 |
Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1997 |
[Hyperfractionated accelerated simultaneous radiochemotherapy in advanced hypopharyngeal carcinomas. Survival rate, retained function quality of life in a phase II study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Co | 1998 |
Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1998 |
Neoadjuvant therapy for organ preservation in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemot | 2000 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
72 other studies available for fluorouracil and Hypopharyngeal Cancer
| Article | Year |
|---|---|
Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents.
Topics: Cell Adhesion Molecules, Neuronal; Cisplatin; Docetaxel; Fluorouracil; Humans; Hypopharyngeal Neopla | 2022 |
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2021 |
Incessant Atrial Tachycardia Following Combination Chemotherapy with Cetuximab, Cisplatin and 5-Fluorouracil for Hypopharyngeal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cetuximab; Cisplatin; Elect | 2021 |
Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cause of Death; | 2018 |
Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-Positive | 2019 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, S | 2014 |
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Che | 2013 |
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2015 |
[Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
EGR1 regulates radiation-induced apoptosis in head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regula | 2015 |
Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
Chemoselection combined with alternating chemoradiotherapy or surgery for hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Protocols; Chemoradiotherapy; Cisplatin; Combined | 2016 |
Definitive Radiotherapy Following Induction Chemotherapy for Hypopharyngeal Cancer: Selecting Candidates for Organ-Preserving Treatment Based on the Response to Induction Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Femal | 2016 |
[Analysis of clinical factors for the efficacy of TPF in treating hypopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Hypopharyngeal Neop | 2015 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutition Diso | 2017 |
Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Comb | 2008 |
Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
Searching for less toxic larynx preservation: a need for common definitions and metrics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2009 |
Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined | 2010 |
[A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophage | 2009 |
Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cisplatin; Combined Modality Therapy; Fl | 2010 |
Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2010 |
Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; D | 2010 |
[Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2010 |
Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra-arterial chemoradiation therapy with three agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
[A case of hypopharyngeal carcinoma in which a complete response to chemotherapy was achieved with docetaxel, cisplatin, 5-FU and levofolinate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2002 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
[Four cases of hypopharyngeal cancer treated with docetaxel, cisplatin, and 5-FU followed by radiotherapy and/or neck dissection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; | 2004 |
[Treatment of hypopharyngeal carcinomas--an institutional analysis of the results of FAR radiochemotherapy, radical resection, and free jejunum flap reconstruction and the indication of neck dissection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cervicoplasty; Cineradiography; Female; Fluor | 2004 |
Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Degluti | 2005 |
Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Li | 2005 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; | 2005 |
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2005 |
[Concurrent chemoradiotherapy for advanced hypopharyngeal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2005 |
Reversible impairment of auditory callosal pathway in 5-fluorouracil-induced leukoencephalopathy: parallel changes in function and imaging.
Topics: Antimetabolites, Antineoplastic; Auditory Pathways; Corpus Callosum; Dementia, Vascular; Dichotic Li | 2006 |
Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biguanide | 2006 |
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 2007 |
Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2007 |
Treatment results and prognostic factors in locally advanced hypopharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
[Treatment results of concurrent chemoradiotherapy with CDDP or CDGP plus 5-FU for carcinoma of the oropharynx and hypopharynx].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2007 |
Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
Regarding Keane et al.'s randomized trial comparing radiation alone to concomitant infusional 5-flurorouracil, bolus mitomycin-C and split-course radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Lary | 1994 |
Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271-279; 1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1996 |
[Perioperative chemotherapy of squamous cell carcinoma of the hypopharynx].
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemot | 1996 |
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Ce | 1997 |
[Thymidylate synthase expression in patients with hypopharyngeal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 1998 |
Reconstruction with free jejunal autograft after circumferential pharyngolaryngectomy: eighty-three cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Combined Modality Therapy; Fem | 1998 |
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Colitis; Cytome | 1999 |
Rapidly progressive glomerulonephritis and carcinoma of the hypopharynx.
Topics: Brachytherapy; Fluorouracil; Glomerulonephritis; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged | 2001 |
Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; En | 2001 |
[A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2002 |
Concomitant chemoradiotherapy in pyriform sinus carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2002 |
[Induction chemotherapy and larynx preservation: is such practice useful?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2002 |
[Vestibulotoxic effects of the cytostatic drug carboplatin in patients with head and neck tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Fluoroura | 1992 |
[Evaluating the effectiveness of chemotherapy in patients with head-neck tumors using positron emission tomography (PET scan)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
[Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers--results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Bone Marr | 1992 |
Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cisplatin; Combined | 1991 |
[Clinical evaluation of hypopharyngeal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Flu | 1991 |
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1991 |
[Induction chemotherapy in cancer of the upper respiratory and digestive tract. Preliminary results of the protocol combining cisplatin, 5-fluorouracil and bleomycin (CFB)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1985 |
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1985 |
A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Therapy, Combination; Female; | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality | 1985 |